Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study. Issue 6 (27th February 2019)

• Record Type: Journal Article
• Authors: Ruane, Peter; Strasser, Simone I.; Gane, Edward J.; Hyland, Robert H.; Shao, Jiang; Dvory‐Sobol, Hadas; Tran, Tram; Stamm, Luisa M.; Brainard, Diana M.; Nyberg, Lisa; Shafran, Stephen
• Is Part Of: Journal of viral hepatitis. Volume 26:Issue 6(2019)
• Page Start: 770
• Page End: 773
• Publication Date: 2019-02-27
• Subjects: hepatitis C virus -- direct‐acting antiviral agents -- retreatment; Hepatitis, Viral -- Periodicals; Hepatitis, Viral, Animal; Hepatitis, Viral, Human; 616.3623
• DOI: 10.1111/jvh.13067
• Languages: English
• ISSNs: 1352-0504

Abstract

Summary: This study evaluated 12‐week retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus (HCV) infection who did not achieve sustained virologic response after previous treatment with a sofosbuvir‐ and velpatasvir‐containing regimen. All 31 patients maintained a sustained virologic response 12 weeks after the last sofosbuvir/velpatasvir/voxilaprevir dose.